亿帆医药：控股子公司在研产品F-652获得临床试验批准通知书

Core Viewpoint - Yifan Pharmaceutical (002019) announced that its subsidiaries, Yiyisheng Biopharmaceutical Development (Shanghai) Co., Ltd. and Yiyisheng Biopharmaceutical (Beijing) Co., Ltd., received approval from the National Medical Products Administration for a clinical trial of their investigational product, F-652, aimed at treating graft-versus-host disease (GVHD) [1] Group 1 - The approved product, F-652, is a recombinant human interleukin 22-Fc fusion protein [1] - The clinical trial is a Phase II study specifically targeting GVHD [1] - No similar products targeting the same mechanism have been approved for market or are currently in clinical development for GVHD in both domestic and international markets [1]